Company / Cash & Equivalents
Natera, Inc. Cash & Equivalents History
FY2016-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$84.4M
FY2021
5-year range
$84.4M / $84.4M
FY2017-FY2021
Trend
+73.4%
vs FY2020
Sector context
#117 of 148
Health Care
What the data says
Natera, Inc.'s cash & equivalents of $84M is lower than 79% of companies in the Health Care sector (FY2021). Cash & Equivalents has fluctuated over the past 6 years, ranging from $13M in FY2017 to $84M in FY2021.
Based on SEC 10-K filings.
$84M in FY2021 with a 5-year CAGR of +40.8%.
Improved from $62M to $84M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +22.1%
- 5-Year CAGR
- +40.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 148This company $84.4M Sector average $1.2B
▼
-92.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +40.8%, indicating consistent growth.
- In FY2021, cash & equivalents increased 73.4% year-over-year.
- Ranks #117 out of 148 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $84.4M | +73.4% |
| FY2020 | $48.7M | -21.4% |
| FY2019 | $61.9M | +33.4% |
| FY2018 | $46.4M | +267.7% |
| FY2017 | $12.6M | -17.3% |
| FY2016 | $15.3M | -47.3% |
As of FY2021 · SEC 10-K · Updated Jun 30, 2026